Atlas Trials

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Clinical trial NCT06393751 · WITHDRAWN

Trial details

NCT number
NCT06393751
Sponsor
National Cancer Institute (NCI)
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube AdenocarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Undifferentiated CarcinomaRecurrent High Grade Endometrioid AdenocarcinomaRecurrent Ovarian AdenocarcinomaRecurrent Ovarian CarcinosarcomaRecurrent Ovarian Clear Cell Adenocarcinoma
Start date
2025-10-31
Primary completion
2028-02-09
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.